Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.0500 |
Ask | 0.8000 |
Strike | 115.00 |
Expiry date | 2024-12-20 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 140 |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.